NASDAQ:VRNA
Verona Pharma plc Stock News
$16.50
+0.360 (+2.23%)
At Close: Mar 27, 2024
Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update
02:00am, Tuesday, 19'th Apr 2022
LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announc
Verona Pharma plc 2021 Q4 - Results - Earnings Call Presentation
07:42pm, Friday, 04'th Mar 2022 Seeking AlphaVerona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2021 Results - Earnings Call Transcript
08:33pm, Thursday, 03'rd Mar 2022 Seeking AlphaVerona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2021 Results - Earnings Call Transcript
03:33pm, Thursday, 03'rd Mar 2022
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2021 Results - Earnings Call Transcript
Verona Pharma: Q4 Earnings Insights
01:10pm, Thursday, 03'rd Mar 2022 Benzinga
Verona Pharma (NASDAQ: VRNA ) reported its Q4 earnings results on Thursday, March 3, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Verona Pharma beat estimated earnings by 16.67%, reporting … Full story available on Benzinga.com
Verona Pharma ADR Earnings Beat, Revenue Inline In Q1 By Investing.com
11:37am, Thursday, 03'rd Mar 2022 Investing.com
Verona Pharma ADR Earnings Beat, Revenue Inline In Q1
Verona Pharma GAAP EPS of -$0.05 beats by $0.30
07:52am, Thursday, 03'rd Mar 2022 Seeking Alpha
Verona Pharma press release (VRNA): Q4 GAAP EPS of -$0.05 beats by $0.30.Cash and cash equivalents at December 31, 2021, were $148.4 M (December 31, 2020: $188.0M)
Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
07:00am, Thursday, 03'rd Mar 2022 GlobeNewswire
Phase 3 ENHANCE program on track to report top-line COPD data in 2022
Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
07:00am, Thursday, 17'th Feb 2022 GlobeNewswire
LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2021 on Thursday, March 3, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
02:00am, Thursday, 17'th Feb 2022
LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster
12:00am, Friday, 04'th Feb 2022 Seeking AlphaVerona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster
07:00pm, Thursday, 03'rd Feb 2022
he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is being developed as a maintenance treatment for chronic obstructive respiratory disease. The stock is
Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference
02:00am, Tuesday, 04'th Jan 2022
LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announce
Canaccord Genuity Boosts Verona Pharma (NASDAQ:VRNA) Price Target to $23.00
10:54am, Monday, 15'th Nov 2021 Transcript Daily
Verona Pharma (NASDAQ:VRNA) had its price objective hoisted by Canaccord Genuity from $18.00 to $23.00 in a report released on Friday morning, Price Targets.com reports. Canaccord Genuity currently has a buy rating on the stock. A number of other brokerages have also recently weighed in on VRNA. Zacks Investment Research cut shares of Verona Pharma []
Verona Pharma (NASDAQ:VRNA) Price Target Increased to $23.00 by Analysts at Canaccord Genuity
10:20am, Monday, 15'th Nov 2021 Dakota Financial News
Verona Pharma (NASDAQ:VRNA) had its price target hoisted by Canaccord Genuity from $18.00 to $23.00 in a research report released on Friday, Analyst Price Targets reports. Canaccord Genuity currently has a buy rating on the stock. Other equities analysts also recently issued reports about the stock. HC Wainwright began coverage on shares of Verona Pharma []